The best of the rest: High­lights from the be­low-the-fold pre­sen­ta­tions at #ES­MO21

This year’s ES­MO Con­gress has had a ma­jor fo­cus on Big Phar­ma drugs — most no­tably can­di­dates from Mer­ck and As­traZeneca — but there have al­so been up­dates from small­er biotechs with da­ta look­ing to chal­lenge the big-name drug­mak­ers.

To­day, we’re high­light­ing some of the da­ta re­leas­es that flew un­der the radar at #ES­MO21 — whether from ear­ly-stage drugs look­ing to make a mark or old­er stal­warts with in­ter­est­ing fol­low-up da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER